Other PHGDH inhibitors, NCT‐502 and NCT‐503 reduce the production of glucose‐derived serine in breast cancer and suppress the growth of PHGDH‐dependent cancer cells in culture and in orthotopic xenograft tumors [98]. The gene discussed is PHGDH; the disease is breast cancer.